Jennifer L.  Good net worth and biography

Jennifer Good Biography and Net Worth

Ms. Good has served as a member of our Board of Directors since June 2019. She is currently the President and Chief Executive Officer of Trevi Therapeutics, a biopharmaceutical company developing nalbuphine ER to treat serious neurologically mediated conditions, which she co-founded in March 2011. Previously, Ms. Good worked at Penwest Pharmaceuticals from 1997 to 2010, where she held various positions including President and Chief Executive Officer, Chief Operating Officer, and Chief Financial Officer, and led the company through its transition from development-stage into a revenue-generating entity. Ms. Good served on the board of Juniper Pharmaceuticals, Inc., a publicly traded healthcare company, from September 2017 until it was acquired by Catalent, Inc. in August 2018. She has also served as a board member of the Friedreich’s Ataxia Research Alliance (FARA), a patient advocacy group advancing treatments for the cure of Friedreich’s ataxia, since 2011, and is the Treasurer for a nonprofit organization, Newtown Youth & Family Services, which provides mental health services and programs to support the community. Ms. Good holds her BBA in accounting from Pacific Lutheran University in 1987 and is a Certified Public Accountant licensed by the State of Washington, although her license is currently inactive.

What is Jennifer L. Good's net worth?

The estimated net worth of Jennifer L. Good is at least $147,060.00 as of September 17th, 2024. Ms. Good owns 3,000 shares of Rhythm Pharmaceuticals stock worth more than $147,060 as of October 24th. This net worth estimate does not reflect any other investments that Ms. Good may own. Learn More about Jennifer L. Good's net worth.

How do I contact Jennifer L. Good?

The corporate mailing address for Ms. Good and other Rhythm Pharmaceuticals executives is 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116. Rhythm Pharmaceuticals can also be reached via phone at (857) 264-4280 and via email at [email protected]. Learn More on Jennifer L. Good's contact information.

Has Jennifer L. Good been buying or selling shares of Rhythm Pharmaceuticals?

Jennifer L. Good has not been actively trading shares of Rhythm Pharmaceuticals during the last quarter. Most recently, Jennifer L. Good sold 31,751 shares of the business's stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $52.40, for a transaction totalling $1,663,752.40. Following the completion of the sale, the director now directly owns 3,000 shares of the company's stock, valued at $157,200. Learn More on Jennifer L. Good's trading history.

Who are Rhythm Pharmaceuticals' active insiders?

Rhythm Pharmaceuticals' insider roster includes Pamela Cramer (Insider), Jennifer Good (Director), Jennifer Lee (EVP), Yann Mazabraud (EVP), David Meeker (CEO), Joseph Shulman (Insider), Hunter Smith (CFO), and Lynn Tetrault (Director). Learn More on Rhythm Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Rhythm Pharmaceuticals?

In the last twelve months, insiders at the sold shares 25 times. They sold a total of 331,893 shares worth more than $15,042,769.51. The most recent insider tranaction occured on September, 17th when Director Jennifer L Good sold 31,751 shares worth more than $1,663,752.40. Insiders at Rhythm Pharmaceuticals own 5.6% of the company. Learn More about insider trades at Rhythm Pharmaceuticals.

Information on this page was last updated on 9/17/2024.

Jennifer L. Good Insider Trading History at Rhythm Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/17/2024Sell31,751$52.40$1,663,752.403,000View SEC Filing Icon  
See Full Table

Jennifer L. Good Buying and Selling Activity at Rhythm Pharmaceuticals

This chart shows Jennifer L Good's buying and selling at Rhythm Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Rhythm Pharmaceuticals Company Overview

Rhythm Pharmaceuticals logo
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $49.02
Low: $48.17
High: $49.63

50 Day Range

MA: $49.24
Low: $44.19
High: $54.55

2 Week Range

Now: $49.02
Low: $21.34
High: $55.64

Volume

387,359 shs

Average Volume

533,367 shs

Market Capitalization

$3.00 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.07